Bioscience Neutraceuticals Inc. (DEVV) financial statements (2021 and earlier)

Company profile

Business Address 500 NORTH MICHIGAN AVENUE #600
CHICAGO, IL 89015
State of Incorp. NV
Fiscal Year End December 31
SIC 59 - Miscellaneous Retail (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments  1 245
Cash and cash equivalents  1 245
Inventory, net of allowances, customer advances and progress billings  3   
Inventory  3   
Prepaid expense 6   4
Total current assets: 65 249
Noncurrent Assets
TOTAL ASSETS: 65 249
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:237991 
Accounts payable   8  
Accrued liabilities59  11 
Interest and dividends payable3112    
Other undisclosed accounts payable and accrued liabilities(88)259   
Debt282828   
Due to related parties 10075844
Other undisclosed current liabilities2112323   
Total current liabilities:2401871341754
Noncurrent Liabilities
Long-term debt and lease obligation44    
Long-term debt, excluding current maturities44    
Total noncurrent liabilities:44    
Total liabilities:2441911341754
Stockholders' equity
Stockholders' equity attributable to parent(244)(185)(130)(17)(3)45
Common stock101111
Additional paid in capital699133114777777
Accumulated deficit(944)(318)(245)(95)(81)(33)
Total stockholders' equity:(244)(185)(130)(17)(3)45
TOTAL LIABILITIES AND EQUITY: 65 249

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues  8   
Cost of revenue
(Cost of Goods and Services Sold)
  (6)   
Gross profit:  2   
Operating expenses(460)(36)(125)(14)(48)(19)
Operating loss:(460)(36)(123)(14)(48)(19)
Nonoperating expense(29)(25)(27)   
Debt instrument, convertible, beneficial conversion feature137     
Other nonoperating expense(166)(25)(27)   
Interest and debt expense(13)(2)    
Loss from continuing operations before equity method investments, income taxes:(502)(63)(150)(14)(48)(19)
Other undisclosed income (loss) from continuing operations before income taxes(124)2    
Loss from continuing operations:(626)(61)(150)(14)(48)(19)
Loss from discontinued operations (12)    
Net loss available to common stockholders, diluted:(626)(74)(150)(14)(48)(19)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(626)(74)(150)(14)(48)(19)
Comprehensive loss, net of tax, attributable to parent:(626)(74)(150)(14)(48)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: